NCT05292664: Venetoclax Basket Trial for High Risk Hematologic Malignancies |
|
|
| Recruiting | 1 | 92 | US | Venetoclax, Venclexta, Azacitidine, Vidaza, Cytarabine, Ara-C, Arabinosylcytosine, Methotrexate, Amethopterin, Methotrexate Sodium, MTX, Hydrocortisone, Cortisone, Hydrocortisone Sodium Succinate, Hydrocortisone Sodium Phosphate, Leucovorin, Calcium Leucovorin,, Citrovorum Factor, Folinic Acid, Dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, Vincristine, Vincristine Sulfate, LCR, VCR, Doxorubicin, Adriamycin, Rubex, Dexrazoxane, Zinecard, Calaspargase Pegol, Asparlas, Erwinia asparaginase, Rylze or native Erwinia asparaginase | Andrew E. Place, MD, AbbVie, Servier, Children's Cancer Research Fund, University of Colorado, Denver, Boston Children's Hospital, Gateway for Cancer Research | Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage | 04/25 | 04/27 | | |
